Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC 50 value of 5.3 nM and a K i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4 -inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
Products | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Others | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > MOFs | Products > Signaling Pathways > Xanthine Oxidase | Products > Signaling Pathways > Cytochrome P450
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.